Tyra Biosciences (NASDAQ:TYRA) Trading 6.5% Higher

Tyra Biosciences, Inc. (NASDAQ:TYRA) was up 6.5% during trading on Monday . The company traded as high as $16.78 and last traded at $16.69. Approximately 53,973 shares traded hands during trading, a decline of 58% from the average daily volume of 129,241 shares. The stock had previously closed at $15.67.

Analysts Set New Price Targets

A number of research analysts have recently commented on TYRA shares. Wedbush reaffirmed an “outperform” rating and set a $28.00 price target on shares of Tyra Biosciences in a research report on Thursday, March 21st. HC Wainwright reissued a “buy” rating and set a $23.00 price objective (up previously from $19.00) on shares of Tyra Biosciences in a report on Wednesday, March 20th.

Tyra Biosciences Trading Up 5.0 %

The firm has a fifty day simple moving average of $17.38 and a two-hundred day simple moving average of $14.85. The stock has a market cap of $863.95 million, a PE ratio of -9.73 and a beta of 1.13.

Tyra Biosciences (NASDAQ:TYRA) last announced its quarterly earnings data on Tuesday, March 19th. The company reported ($0.53) EPS for the quarter, missing the consensus estimate of ($0.48) by ($0.05). Equities analysts forecast that Tyra Biosciences, Inc. will post -1.89 earnings per share for the current year.

Insider Activity at Tyra Biosciences

In other Tyra Biosciences news, COO Daniel Bensen sold 1,501 shares of Tyra Biosciences stock in a transaction that occurred on Monday, February 12th. The stock was sold at an average price of $20.00, for a total value of $30,020.00. Following the transaction, the chief operating officer now directly owns 451,480 shares of the company’s stock, valued at approximately $9,029,600. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In the last three months, insiders have sold 15,816 shares of company stock valued at $298,165. Corporate insiders own 15.40% of the company’s stock.

Hedge Funds Weigh In On Tyra Biosciences

Hedge funds have recently made changes to their positions in the business. Wellington Management Group LLP increased its stake in shares of Tyra Biosciences by 18.5% during the third quarter. Wellington Management Group LLP now owns 94,112 shares of the company’s stock valued at $1,296,000 after buying an additional 14,676 shares during the period. Exchange Traded Concepts LLC boosted its position in shares of Tyra Biosciences by 34.0% during the fourth quarter. Exchange Traded Concepts LLC now owns 9,531 shares of the company’s stock valued at $132,000 after purchasing an additional 2,417 shares in the last quarter. Simplex Trading LLC boosted its position in shares of Tyra Biosciences by 198.1% during the third quarter. Simplex Trading LLC now owns 2,009 shares of the company’s stock valued at $27,000 after purchasing an additional 1,335 shares in the last quarter. Corton Capital Inc. bought a new stake in shares of Tyra Biosciences during the third quarter valued at approximately $152,000. Finally, Bank of New York Mellon Corp boosted its position in shares of Tyra Biosciences by 2.6% during the third quarter. Bank of New York Mellon Corp now owns 41,870 shares of the company’s stock valued at $577,000 after purchasing an additional 1,074 shares in the last quarter. 84.14% of the stock is owned by hedge funds and other institutional investors.

Tyra Biosciences Company Profile

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.